Search
                    Richmond, VA Paid Clinical Trials
A listing of 604  clinical trials  in Richmond, VA  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            433 - 444 of 604
        
                There are currently 604 clinical trials in Richmond, Virginia looking for participants to engage in research studies. Trials are conducted at various facilities, including Virginia Commonwealth University, Virginia Commonwealth University/Massey Cancer Center, VCU Massey Comprehensive Cancer Center and Virginia Cancer Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you. 
            
                                        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
                                
            
            
        Recruiting
                            
            
                The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/05/2025
            
            Locations: HCA Chippenham Hospital, Richmond, Virginia  +1 locations         
        
        
            Conditions: Heart Failure
        
            
        
    
                
                                    HEAL-IST IDE Trial
                                
            
            
        Recruiting
                            
            
                Inappropriate Sinus Tachycardia (IST) is a prevalent and debilitating condition in otherwise healthy younger patients, resulting in significant loss of quality of life, lacking effective treatment options or systematic clinical evidence to support a therapy. The primary objective of this clinical trial is to evaluate the safety and effectiveness of a hybrid sinus node sparing ablation procedure for the treatment of symptomatic drug refractory or drug intolerant IST.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 75 years
            Trial Updated:
                05/05/2025
            
            Locations: Virginia Commonwealth University, Richmond, Virginia         
        
        
            Conditions: Inappropriate Sinus Tachycardia
        
            
        
    
                
                                    Intestinal Microbiota Transplant in Alcohol-Associated Liver Disease
                                
            
            
        Recruiting
                            
            
                The purpose of this research study is to test the safety, tolerability, and effectiveness of the capsules that contain bacteria from healthy individuals when used to treat alcohol craving and drinking.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/05/2025
            
            Locations: Hunter Holmes McGuire VA Medical Center, Richmond, Virginia  +1 locations         
        
        
            Conditions: Liver Disease; Alcohol-Related, Cirrhosis, Alcohol Use Disorder
        
            
        
    
                
                                    Effectiveness of Immersive Virtual Reality Combined With Task-Specific Training on Hemiplegic Arm Function Following Stroke
                                
            
            
        Recruiting
                            
            
                The purpose of this research study is to understand the efficacy of using an immersive Virtual Reality (VR) environment, with task-specific training, to encourage arm movement following stroke.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/05/2025
            
            Locations: Virginia Commonwealth University, Richmond, Virginia         
        
        
            Conditions: Stroke
        
            
        
    
                
                                    Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
                                
            
            
        Recruiting
                            
            
                This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD. The primary objective of the study is to evaluate the PoC for efficacy in a population with SSc-ILD. While improvement of ILD is the outcome of interest, the study will also evaluate changes in the skin. After initial screening (up to 4 weeks), approximately 25 eligible participants will be randomized 2:2:1 to 1...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/05/2025
            
            Locations: aTyr Investigative Site, Richmond, Virginia         
        
        
            Conditions: Interstitial Lung Disease
        
            
        
    
                
                                    A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
                                
            
            
        Recruiting
                            
            
                TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.             
        
        
    Gender:
                ALL
            Ages:
                All
            Trial Updated:
                05/02/2025
            
            Locations: Virginia Commonwealth University, Richmond, Virginia         
        
        
            Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
        
            
        
    
                
                                    Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
                                
            
            
        Recruiting
                            
            
                A randomized trial of adjuvant Pembrolizumab following surgical resection versus observation following surgical resection in patients with stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm.
Patients will be randomized (1:1) 4-12 weeks following surgery to either:
* Arm A: Pembrolizumab 400 mg every 6 weeks × 9 cycles
* Arm B: Observation
Stratification factors will include: PD-L1 TPS (\<50% vs. ≥50%), and tumor size (1-2 cm vs. \>2-4 cm)             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/01/2025
            
            Locations: Virginia Commonwealth University, Richmond, Virginia         
        
        
            Conditions: NSCLC, Stage I
        
            
        
    
                
                                    Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
                                
            
            
        Recruiting
                            
            
                This Phase III trial will examine the efficacy of computerized cognitive training methods on perceived cognitive impairment in breast cancer survivors.             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 100 years
            Trial Updated:
                05/01/2025
            
            Locations: Bon Secours Richmond Community Hospital, Richmond, Virginia  +4 locations         
        
        
            Conditions: Breast Cancer, Cognitive Impairments
        
            
        
    
                
                                    Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors
                                
            
            
        Recruiting
                            
            
                This phase III trial studies how well bupropion works in reducing cancer related fatigue in cancer survivors. Cancer and its treatment can cause fatigue. Bupropion is a drug that is used to treat depression, as well as to help people quit smoking. It belongs to the family of drugs called antidepressants and works by increasing certain types of activity in the brain. Bupropion may reduce cancer-related fatigue by causing changes in inflammation and stress hormones.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/30/2025
            
            Locations: Bon Secours Richmond Community Hospital, Richmond, Virginia  +2 locations         
        
        
            Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
        
            
        
    
                
                                    An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
                                
            
            
        Recruiting
                            
            
                This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/30/2025
            
            Locations: Bon Secours Saint Mary's Hospital, Richmond, Virginia  +1 locations         
        
        
            Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
        
            
        
    
                
                                    Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
                                
            
            
        Recruiting
                            
            
                Liposorber® LA-15 System is a blood purification therapy that selectively removes malignant lipoproteins including low density lipoprotein from circulating blood flow and rapidly reduces the plasma cholesterol level. The system was originally developed for the treatment of patients with serious dyslipidemia such as familial hypercholesterolemia and then applied to improve the dyslipidemia, a common complication of nephrotic syndrome and found to bring about improvement not only with the dyslipid...  Read More             
        
        
    Gender:
                ALL
            Ages:
                21 years and below
            Trial Updated:
                04/29/2025
            
            Locations: Children's Hospital of Richmond at VCU, Richmond, Virginia         
        
        
            Conditions: Focal Segmental Glomerulosclerosis
        
            
        
    
                
                                    Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
                                
            
            
        Recruiting
                            
            
                This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients w...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                04/29/2025
            
            Locations: Bon Secours Mercy Health - Richmond Market, Richmond, Virginia         
        
        
            Conditions: Aortic Valve Stenosis, Mitral Regurgitation
        
            
        
    433 - 444 of 604
            